Stine Bordier Høj

Stine Bordier Høj

Auto-generated profile, based on publicly available information

Stine Bordier Høj

Centre de recherché du Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2010 in Journal of Consumer Behaviour
Verified
Journal Article
Closed access
PDF file
Anne Sharp (now Souvertjis)Anne Sharp (now Souvertjis)
Anne Sharp (now Souvertjis)
SHStine Høj
Stine Høj
MWMeagan Wheeler
Meagan Wheeler

1 January 2020 in American Journal of Public Health
Verified
Journal Article
Closed access
BJBrendan Jacka
Brendan Jacka
SLSarah Larney
Sarah Larney
LDLouisa Degenhardt
Louisa Degenhardt
NJNaveed Zafar Janjua
Naveed Zafar Janjua
SHStine Høj
Stine Høj
JBJulie Bruneau
Julie Bruneau
Objectives. To determine the number of people who inject drugs (PWID) in Canada and the annual coverage of opioid agonist treatment (OAT) and needle-and-syringe provision for PWID. Methods. We estimated the number of PWID in 11 of 13 Canadian provinces and territories in 2011 by using indirect multiplier methods based on provincial and territorial methadone recipient totals and proportion of surveyed PWID receiving methadone. We modeled annual increases for 2011 to 2016 on Quebec and British Columbia longitudinal data. We calculated needle-and-syringe coverage (World Health Organization [WHO] recommendation: ≥ 200 per PWID) and OAT coverage (WHO recommendation: ≥ 40 per 100 PWID) per province and territory annually. Results. An estimated 130 000 individuals in Canada (0.55%) injected drugs in 2011, increasing to 171 900 individuals (0.70%) in 2016. Needle-and-syringe coverage increased from 193 to 291 per PWID, and OAT coverage increased from 55 to 66 per 100 PWID over the study period. Conclusions. While the number of PWID increased between 2011 and 2016, OAT coverage remained high, and needle-and-syringe coverage generally improved over time. Public Health Implications. These data will inform public health surveillance, service planning, and resource allocation, and assist monitoring of treatment and harm-reduction coverage outcomes.

23 September 2014 in Waste Management & Research: The Journal for a Sustainable Circular Economy
Verified
Journal Article
Closed access
Christian ReynoldsChristian Reynolds
Christian Reynolds
VMVicki Mavrakis
Vicki Mavrakis
SDSandra Davison
Sandra Davison
SHStine B Høj
Stine B Høj
EVElisha Vlaholias
Elisha Vlaholias
DDDrew Dawson
Drew Dawson
Food waste is a global problem. In Australia alone, it is estimated that households throw away AU$5.2 billion worth of food (AU$616 per household) each year. Developed countries have formal waste management systems that provide measures of food waste. However, much remains unknown about informal food waste disposal routes and volumes outside of the formal system. This article provides indicative metrics of informal food waste by identifying, in detail, five of the dominant informal food waste disposal routes used by Australian households: home composting, feeding scraps to pets, sewer disposal, giving to charity, and dumping or incineration. Informal waste generation rates are then calculated from three primary data sources, in addition to data from previous Australian and UK surveys, using a weighted average method in conjunction with a Monte-Carlo simulation. We find that the average Australian household disposes of 2.6 kgs of food waste per week through informal routes (1.7 kgs via household composting, 0.2 kgs via animals, and 0.6 kgs via sewage). This represents 20% of Australian household food waste flows. Our results highlight that informal food waste is a sizable food waste flow from Australian homes, deserving of greater research and government attention. Our examination of the full extent of food waste by disposal mode provides waste managers and policy makers with clear disposal routes to target for behaviour change and positive environmental outcomes.

1 October 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
SHStine Bordier Høj
Stine Bordier Høj
BJBrendan Jacka
Brendan Jacka
NMNanor Minoyan
Nanor Minoyan
AAAndreea Adelina Artenie
Andreea Adelina Artenie
JBJulie Bruneau
Julie Bruneau

28 April 2019 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
AAAndreea A. Artenie
Andreea A. Artenie
NMNanor Minoyan
Nanor Minoyan
BJBrendan Jacka
Brendan Jacka
SHStine Høj
Stine Høj
DJDidier Jutras-Aswad
Didier Jutras-Aswad
JBJulie Bruneau
Julie Bruneau
BACKGROUND: Opioid agonist treatment is considered important in preventing acquisition of hepatitis C virus (HCV) among people who inject drugs; however, the role of dosage in opioid agonist treatment is unclear. We investigated the joint association of prescribed dosage of opioid agonist treatment and patient-perceived dosage adequacy with risk of HCV infection among people who inject drugs. METHODS: We followed prospectively people who inject drugs at risk of acquiring HCV infection (who were RNA negative and HCV-antibody negative or positive) in Montréal, Canada (2004–2017). At 6-month, then 3-month intervals, participants were tested for HCV antibodies or RNA, and completed an interviewer-administered behavioural questionnaire, reporting the following: current exposure to opioid agonist treatment (yes/no), prescribed dosage either high (methadone ≥ 60 mg/d or buprenorphine ≥ 16 mg/d) or low, and perceived dosage adequacy (adequate/inadequate). We then assigned participants to 1 of 5 exposure categories: no opioid agonist treatment, high dosage of opioid agonist treatment perceived to be adequate, high dosage perceived to be inadequate, low dosage perceived to be adequate or low dosage perceived to be inadequate. To estimate associations between categories of opioid agonist treatment dosage and incident HCV infection, we conducted Cox regression analyses, adjusting for multiple confounding factors. RESULTS: Of 513 participants (median age 35.0 yr, 77.6% male), 168 acquired HCV over 1422.6 person-years of follow-up (incidence 11.8/100 person-years, 95% confidence interval [CI] 10.1–13.7). We observed a gradient in the relative risks of HCV infection across categories of opioid agonist treatment dosage. Compared with people who inject drugs not receiving opioid agonist treatment, adjusted hazard ratios were 0.43 (95% CI 0.23–0.84) for those receiving high dosages perceived to be adequate, 0.61 (95% CI 0.25–1.50) for those receiving high dosages perceived to be inadequate, 1.22 (95% CI 0.74–2.00) for those receiving low dosages perceived to be adequate and 1.94 (95% CI 1.11–3.39) for those receiving low dosages perceived to be inadequate. INTERPRETATION: Risk of HCV infection varies considerably according to dosage of opioid agonist treatment and patient-perceived adequacy, with associations indicating both protective and harmful effects relative to no exposure to opioid agonist treatment.

1 March 2021 in Health & Place
Verified
Journal Article
Closed access
SHStine Bordier Høj
Stine Bordier Høj
Catherine PaquetCatherine Paquet
Catherine Paquet
JCJean Caron
Jean Caron
MDMark Daniel
Mark Daniel